Filing Flows › Health Care › Kyntra Bio (KYNB)
Kyntra Bio (KYNB) earnings and revenue breakdown
Latest: Q1 2026 · 10-Q filed May 12, 2026 · Kyntra Bio (KYNB) Q1 2026 earnings results →
Q1 2026 Revenue up 36% year over year to $3.7M · 407¢ of every $1 of revenue lost · operating margin -369.7%
Kyntra Bio made $3.7M in Q1 2026 (+36% Y/Y): Drug Product Revenue $3.5M, Development and Other Revenue $246K. Operating margin -369.7%, net loss $15.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3.7M in Q1 2026, up 36% year over year and up 193% from the previous quarter. Drug Product Revenue was the largest line at 93% of revenue. Drug Product Revenue added $897K year over year (up 35%), 90% of the total change.
Operating costs exceeded revenue by $13.8M, an operating margin of -369.7%. Total costs fell 1% while revenue rose 36%. The fastest-growing cost line was Cost of revenue (+1529%). The quarter ended with a net loss of $15.2M, wider than the previous quarter's $14.2M loss.
Operating cash flow was −$13.9M. Non-cash charges added back $1.2M of share-based compensation.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2026 | 10-Q | May 12, 2026 | $3.7M | +36% | -369.7% | −$15.2M | −$13.9M |
| Q4 2025 | 10-K | Mar 16, 2026 | $1.3M | -59% | n/m | −$14.2M | −$18.3M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $1.1M | -98% | -502.9% | $201M | −$1.8M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $1.3M | +35% | -894.1% | −$7.6M | $12.7M |
| Q1 2025 | 10-Q | May 12, 2025 | $2.7M | -89% | -544.7% | $4.6M | $2.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Kyntra Bio
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com .
In its own words, from its 8-K, filed Aug 13, 2026.
Kyntra Bio against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +36% against the peers' median +10%. Operating margin: -369.7% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| KYNB Kyntra Bio | Q1 2026 | $3.7M | +36% | -369.7% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Kyntra Bio 10-Q on SEC EDGAR · CIK 921299 · Pharmaceutical Preparations
13F: who owns KYNB and who is buying
More on KYNB
History
Every quarter: Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results